Melanoma Therapeutic Resistance:<br />Interface between Mutation and Checkpoint Targeted Therapies

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 MAPK and PD-1 targeted therapies for advanced melanoma

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Mechanisms of acquired and innate resistance to anti-PD-1 therapy

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Slide 4

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 MAPK-dependent and -redundant mechanisms of MAPKi resistance

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Slide 6

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Pervasive epigenomic and immune compartment evolution of MAPKi resistant melanoma

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Biopsies of regressing and residual melanoma on MAPKi thearpy

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 MAPKi-induced epigenomic switch:<br />cell line models vs. regressing melanoma from patients

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Co-evolution of tumor cell and stromal/immune compartments

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Induction of IPRES signatures in regressing melanoma on MAPKi

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 A set of signatures co-enriched in pretreatment<br />melanoma non-responsive to anti-PD-1 therapy

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Slide 13

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 IPRES signature defines a transcriptomic subset of melanoma

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Co-enrichment of IPRES defines a pan-cancer sub-type

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Relationship between T-cell Inflammation and IPRES<br />(The Cancer Genome Atlas or TCGA melanoma)

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Influence of MAPKi therapy on IPRES/IFN transcriptomic subsets<br />

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Recapitulating the natural history of BRAF mutant melanoma on MAPKi therapy

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 BRAFi induces temporally dynamic shifts in<br /> IPRES/IFN transcriptomic states

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Summary

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium

 Thanks to...

Presented By Roger Lo at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium